Heron Therapeutics (HRTX) Q4 2024 earnings summary

Executive summary

• Achieved profitability in Q4 and full year 2024, with Q4 net income of $3.6 million and full-year net revenue of $144.2 million, up 14% year-over-year.

• Major milestones included expanded ZYNRELEF labeling, favorable CMS reimbursement, CrossLink partnership, and VAN device launch.

• U.S. District Court upheld CINVANTI patents, securing exclusivity through 2035.

Financial highlights

• Q4 2024 net income was $3.6–$3.7 million; full-year adjusted EBITDA was $8.6 million.

• Net revenues for 2024 reached $144.2 million, a 14% increase year-over-year.

• Gross margin improved to 73% in 2024 from 49% in 2023.

• Cash and short-term investments at year-end totaled $59.3 million.

• Operating expenses for 2024 declined significantly year-over-year.

Outlook and guidance

• 2025 net revenue guidance: $153–$163 million; adjusted EBITDA: $0–$8 million.

• ZYNRELEF and APONVIE expected to drive growth, with NOPAIN Act reimbursement starting April 2025.

• Anticipates continued CINVANTI unit growth but at lower prices due to competition.

• Operating expenses expected to be slightly higher in 2025 due to increased R&D and legal costs.